Fighting disease

We need new antibiotics to beat superbugs, but why are they so hard to find?

We’re in a protracted war against superbugs because we’ve overused existing antibiotics: a key weapon against disease.

We’ve heard a lot lately about superbugs – bacteria that are resistant to current antibiotics. But as the threat of superbugs continues to rise, the number of new treatments available has flatlined. This has placed us dangerously close to the edge of a return to the pre-antibiotic era, when even simple infections caused death.

We’ve developed antibiotics in the past, so why it is now so difficult to discover and develop new antibiotics? To find out, let’s look back to the “golden age” of antibiotic discovery from the 1940 to 1970s.

How we found antibiotics in the past

The majority of antibiotics we use at home or in hospitals today have their origins in natural products.

The penicillins, cephalosporins, aminoglycosides, rifamycins, tetracyclines and glycopeptide-based antibiotics all came from bacteria or fungi. They were made by nature in response to selective evolutionary pressure over eons of “chemical warfare”, in which microorganisms battled to survive by killing off their competitors with antibiotics.

In the past, the toolkit to develop new antibiotics was simple. Matej Kastelic/Flickr

Of course, they also co-evolved resistance mechanisms to avoid being killed by their own compounds, so antibiotic resistance is equally ancient. Scientists have found antibiotic resistance genes in bacteria isolated from 30,000-year-old permafrost, long before antibiotics were discovered and used by humans.

Most antibiotics found during the “golden age” were from micro-organisms themselves, isolated from soil or plants and then cultured in the laboratory. They were easily screened on agar culture plates or liquid culture broths to see if they could kill pathogenic bugs.

The toolkit required was pretty simple: some dirt, a culture flask to grow the antibiotic-producing bacteria or fungi, a column to separate and isolate the potential new antibiotic, and a culture plate and incubator to test if the compound could kill a disease-causing pathogenic bacteria.

Chemists were then able to “tweak” these new structures to extend their activity against different bacteria and improve their ability to treat infection in the clinic. Most of the antibiotics we have are derived from just one soil-dwelling bacterial order – the Actinomycetales.

Most antibiotics we use were derived from soil-dwelling bacteria. whitaker/Shutterstock

The problem is that by using this tried and trusted method over and over again, we have found all of the low-hanging fruit antibiotics. So scientists have been forced to look further afield, turning to coral reefs, deep oceans and cave-dwelling bacteria to search for new promising molecules.

Key challenges

Philosopher Sun Tzu said “the supreme art of war is to subdue the enemy without fighting”. We are now in a protracted war against superbugs, as we have overplayed a key weapon against disease. Our unfortunate misuse and abuse of antibiotics means that bacteria have developed new ways to inactivate the drugs, to stop them getting to their targets within the bacteria cells, and to pump them back out of the cell when they do get in.

The cost and time required to bring new drugs to market are staggering. Estimates for the time to bring a new antibiotic through the preclinical, clinical and regulatory approval process are in the order of 13 to 15 years and around US$1.2 billion. If the costs of failures are factored in, it is closer to $2.5 billion.

Because we expect to pay $20 or at most $200 for a course of antibiotics (compared to more than $20,000 for many cancer treatments), and because we only take antibiotics for a week or two, almost all of the companies that were active in antibiotic discovery have left the field over the last 20 years.

What are scientists doing?

It’s not all doom and gloom. Scientists have developed many innovative approaches to the search for new antibiotics, such as one recently reported in Nature, in which bacteria from soil are sealed into 10,000 separate miniature culture cells in a chip device, then buried in the soil they came from again to grow in their natural environment. The chip device is then dug up, and each cell screened for compounds that can kill pathogenic bacteria.

Developing new antibiotics is a long and expensive process. Jenni Konrad/Flickr

This type of approach led to the discovery of one of the very few new candidate antibiotics in the last 30 years, teixobactin.

This type of innovation illustrates an important maxim: with good people, the right motivation, perseverance, and sufficient funding we can start to fix some of problems we face in this area.

What are governments doing?

Fortunately, governments around the world have started to respond.

British Prime Minister David Cameron and Chief Medical Officer Dame Sally Davis have been consistent vocal supporters of a cross-government strategy and action plan against superbugs. In fact, Dame Davies recognised that the threat from infections resistant to frontline antibiotics was so serious that she called for the issue to be added to the UK government’s national risk register of civil emergencies, alongside pandemic influenza and terrorism.

The European Union has stepped up with the Innovative Medicines Initiative, Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. They have pledged more than €680 million to fund drug-discovery platforms for antibiotics; new treatments for cystic fibrosis; hospital-acquired pneumonia and urinary tract infections; understanding how drugs get into, and then stay inside bacteria; and new ways of designing and implementing efficient clinical trials for novel antibiotics.

Scientists have been forced to look to coral reefs, deep oceans and cave-dwelling bacteria to search for promising new molecules. ©UCAR/Flickr

In the United States, the National Institutes of Health invest more than $5 billion (17% of total funds) into infectious diseases research, making it second only to cancer research at $5.4 billion (18%). In a further show of support, US President Barack Obama also announced an Executive Order commanding a dozen government agencies to action a comprehensive action plan against superbugs.

Yes, we’ve heard a lot lately about superbugs.

Now it’s time to act.

This post originally appeared on The Conversation.

We welcome your comments at
Sponsored Content BY 

Why should inclusion matter to companies?

It's not just about goodwill - inclusivity is a good business decision.

To reach a 50-50 workplace scenario, policies on diversity need to be paired with a culture of inclusiveness. While diversity brings equal representation in meetings, board rooms, promotions and recruitment, inclusivity helps give voice to the people who might otherwise be marginalized or excluded. Inclusion at workplace can be seen in an environment that values diverse opinions, encourages collaboration and invites people to share their ideas and perspectives. As Verna Myers, a renowned diversity advocate, puts it “Diversity is being invited to the party, inclusion is being asked to dance.”

Creating a sense of belonging for everyone is essential for a company’s success. Let’s look at some of the real benefits of a diverse and inclusive workplace:

Better decision making

A whitepaper by Cloverpop, a decision making tool, established a direct link between inclusive decision making and better business performance. The research discovered that teams that followed an inclusive decision-making process made decisions 2X faster with half the meetings and delivered 60% better results. As per Harvard Business School Professor Francesca Gino, this report highlights how diversity and inclusion are practical tools to improve decision making in companies. According to her, changing the composition of decision making teams to include different perspectives can help individuals overcome biases that affect their decisions.

Higher job satisfaction

Employee satisfaction is connected to a workplace environment that values individual ideas and creates a sense of belonging for everyone. A research by Accenture identified 40 factors that influence advancement in the workplace. An empowering work environment where employees have the freedom to be creative, innovative and themselves at work, was identified as a key driver in improving employee advancement to senior levels.


A research by stated the in India, 62% of innovation is driven by employee perceptions of inclusion. The study included responses from 1,500 employees from Australia, China, Germany, India, Mexico and the United States and showed that employees who feel included are more likely to go above and beyond the call of duty, suggest new and innovative ways of getting work done.

Competitive Advantage

Shirley Engelmeier, author of ‘Inclusion: The New Competitive Business Advantage’, in her interview with Forbes, talks about the new global business normal. She points out that the rapidly changing customer base with different tastes and preferences need to feel represented by brands. An inclusive environment will future-proof the organisation to cater to the new global consumer language and give it a competitive edge.

An inclusive workplace ensures that no individual is disregarded because of their gender, race, disability, age or other social and cultural factors. Accenture has been a leading voice in advocating equal workplace. Having won several accolades including a perfect score on the Human Rights Campaign’s Corporate equality index, Accenture has demonstrated inclusive and diverse practices not only within its organisation but also in business relationships through their Supplier Inclusion and Diversity program.

In a video titled ‘She rises’, Accenture captures the importance of implementing diverse policies and creating an inclusive workplace culture.


To know more about inclusion and diversity, see here.

This article was produced by the Scroll marketing team on behalf of Accenture and not by the Scroll editorial team.